Gremlin is a novel agonist of the major pro-angiogenic receptor VEGFR2 by Mitola S et al.
doi:10.1182/blood-2010-06-291930
Prepublished online July 21, 2010;
2010 116: 3677-3680
 
 
 
 
Luca Zammataro and Marco Presta
Stefania Mitola, Cosetta Ravelli, Emanuela Moroni, Valentina Salvi, Daria Leali, Kurt Ballmer-Hofer,
 
Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2
 http://bloodjournal.hematologylibrary.org/content/116/18/3677.full.html
Updated information and services can be found at:
 (335 articles)Vascular Biology   
 (1546 articles)Brief Reports   
Articles on similar topics can be found in the following Blood collections
 http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
 http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
 http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
 Copyright 2011 by The American Society of Hematology; all rights reserved.
Washington DC 20036.
by the American Society of Hematology, 2021 L St, NW, Suite 900, 
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly
 
 
 
 
 personal use only.
For at Biblioteca della Facoltà di Medicina e Chirurgia on May 11, 2012. bloodjournal.hematologylibrary.orgFrom 
VASCULAR BIOLOGY
Brief report
Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2
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The bone morphogenic protein antago-
nist gremlin is expressed during embry-
onic development and under different
pathologic conditions, including cancer.
Gremlin is a proangiogenic protein be-
longing to the cystine-knot superfamily
that includes transforming growth fac-
tor- proteins and the angiogenic vascu-
lar endothelial growth factors (VEGFs).
Here, we demonstrate that gremlin binds
VEGF receptor-2 (VEGFR2), the main
transducer of VEGF-mediated angiogenic
signals, in a bone morphogenic protein–
independent manner. Similar to VEGF-A,
gremlin activates VEGFR2 in endothelial
cells, leading to VEGFR2-dependent an-
giogenic responses in vitro and in vivo.
Gremlin thus represents a novel proangio-
genic VEGFR2 agonist distinct from the
VEGF family ligands with implications in
vascular development, angiogenesis-de-
pendent diseases, and tumor neovascu-
larization. (Blood. 2010;116(18):3677-3680)
Introduction
The bone morphogenic protein (BMP) antagonist gremlin1 induces
angiogenesis in a BMP-independent manner by binding to as-yet-
unidentified endothelial cell (EC) membrane receptors and activat-
ing multiple tyrosine kinase–dependent intracellular signaling
pathways in ECs.2,3 Gremlin is produced by human tumors4,5 and is
expressed by fibroblast growth factor-2 (FGF2)–activated ECs and
tumor endothelium.2 Thus, gremlin may play paracrine/autocrine
roles in tumor neovascularization. The identification of the EC
receptors activated by gremlin has so far been unsuccessful.
Vascular endothelial growth factor receptor-2 (VEGFR2) is the
major proangiogenic tyrosine kinase receptor expressed by ECs
and is activated by different members of the vascular endothelial
growth factor (VEGF) family.6 Both gremlin and VEGFs belong to
the cystine-knot protein superfamily,7 suggesting possible struc-
tural and/or functional similarities among these proangiogenic
factors. On this basis, we investigated the capacity of gremlin to
interact with and activate VEGFR2. The results demonstrate that
gremlin binds and activates VEGFR2, leading to VEGFR2-
dependent angiogenic responses in vitro and in vivo.
Methods
Ligand-receptor interaction assays
Interaction of VEGF-A and gremlin (R&D Systems) with the immobilized
extracellular domain of VEGFR2 (sVEGFR2; Calbiochem) was analyzed
by surface plasmon resonance (BIAcore Inc) and by competitive enzyme-
linked immunosorbent assay (ELISA). VEGFR2 interaction on the EC
surface was characterized by cross-linking experiments, whereas VEGFR2
dimerization was assessed by fluorescence resonance energy transfer
analysis.
In vitro angiogenic assays
Motility and 3-dimensional gel invasion assays were performed on human,
murine, and bovine ECs.3 When indicated, ECs were stably transfected with
a pcDNA3.1 expression vector harboring the mouse VEGFR2 complemen-
tary DNA.
In vivo angiogenic assays
Alginate beads (5 L) containing gremlin (100 ng per embryo) were
grafted on the chorioallantoic membrane (CAM) of fertilized chicken eggs
at day 11. After 72 hours, new blood vessels converging toward the implant
were counted.
Details of experimental procedures and analysis are provided in
supplemental Methods (available on the Blood Web site; see the Supplemen-
tal Materials link at the top of the online article).
Results and discussion
Surface plasmon resonance analysis was used to assess the ability
of gremlin to bind the extracellular domain of VEGFR2. As shown
in Figure 1A, gremlin binds sVEGFR2 immobilized on a BIAcore
sensor chip (Kd  47  15 nM). The interaction is inhibited by an
excess of soluble sVEGFR2-Fc but not by sVEGFR1-Fc, sVEGFR3-
Fc, or sFGFR1-Fc (Figure 1B). Similar to VEGF-E, gremlin
inhibits the binding of VEGF-A to immobilized sVEGFR2-Fc in
competitive ELISA but, unlike the VEGFR1-specific agonist
placenta growth factor, it does not affect VEGF-A interaction with
sVEGFR1-Fc (Figure 1C). To assess whether gremlin/VEGFR2
interaction occurs also under physiologic conditions, we incubated
human umbilical vein ECs (HUVECs) with gremlin conjugated
with a bifunctional photoactivable biotin-label transfer cross-linker
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(sulfo-gremlin). After photoactivation of EC-bound sulfo-gremlin,
VEGFR2 immunocomplexes were separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis under reducing condi-
tions to transfer the biotin moiety to the interacting receptor,
followed by detection with streptavidin–horseradish peroxidase. As
shown in Figure 1D, sulfo-gremlin forms a 250 kDa biotin–
VEGFR2 complex when cross-linked to the HUVEC surface,
VEGFR2 biotinylation being inhibited by an excess of unlabeled
gremlin or VEGF-A. Taken together, these data demonstrate the
capacity of gremlin to bind VEGFR2 and to compete with VEGF-A
for receptor interaction.
We next investigated whether gremlin induces VEGFR2 auto-
phosphorylation in ECs.6 In HUVECs, gremlin induced a dose-
dependent phosphorylation of tyrosine phosphorylation sites Y1175
and Y951 of VEGFR2 (supplemental Figure 1a) with kinetics
similar to VEGF-A (Figure 2A-B). VEGFR2 activation is also
abrogated by the VEGFR2 tyrosine kinase inhibitor SU54168 both
in gremlin and VEGF-A–activated ECs (Figure 2C). Accordingly,
VEGFR2 phosphorylation, abrogated by SU5416, was observed in
fetal bovine aortic VEGFR2-GM7373 ECs stimulated by gremlin
or VEGF-A after immunostaining with anti–phospho-VEGFR2
(pY1175) antibodies (supplemental Figure 2). VEGFR2 engage-
ment leads to a rapid internalization of the activated receptor.9
Indeed, confocal analysis shows that both gremlin and VEGF-A
induce VEGFR2 phosphorylation and internalization of the acti-
vated receptor in HUVECs (Figure 2D). In addition, fluorescence
resonance energy transfer analysis of bovine aortic ECs cotransfected
with enhanced yellow fluorescent protein–tagged and enhanced cyan
fluorescent protein–tagged VEGFR2 highlighted the internalization of
VEGFR2 dimers in the early endosomal compartment9 after stimulation
with gremlin or VEGF-A but not with FGF2 (supplemental Figure 3).
Thus, in keeping with its ability to induce focal adhesion kinase,
mitogen-activated protein kinase extracellular signal-regulated kinase1/2,
and transcription factor nuclear factor B activation,2,3 gremlin activates
VEGFR2 similar to VEGF-A. Tyrosine phosphorylation of cellular
proteins (supplemental Figure 1a), chemotactic migratory response and
small GTPase Rac activation (supplemental Figure 4), as well as the
formation of 3-dimensional EC sprouts (Figure 2E) are similar in
HUVECs stimulated by either gremlin or VEGF-A. These activities are
blocked by SU5416 or by receptor-binding competitors such as neutral-
izing anti-VEGFR2 antibody10 or the cyclic peptide cyclo-VEGI
(Calbiochem).11
To further assess the role of VEGFR2 in mediating the
proangiogenic activity of gremlin, we transfected murine aortic
ECs (MAECs) expressing low levels of VEGFR2 with a murine
VEGFR2 complementary DNA giving rise to VEGFR2-MAECs.
The motogenic activity exerted by gremlin or VEGF-A is dramati-
cally up-regulated in these cells compared with parental MAECs.
Again, the activity of both motogens is inhibited by SU5416 and
cyclo-VEGI (supplemental Figure 5).
Figure 1. Gremlin binds VEGFR2. (A) sVEGFR2D1-7 (Calbiochem) was immobilized at
approximately .083 pmol/mm2 to a CM5 sensorchip (BIAcore) that was previously activated
with a mixture of 0.2M N-ethyl-N-(3-dimethylaminopropyl)-carbodiimide hydrochloride and
0.05M N-hydroxysuccinimide (35 L; flow rate: 10 L/min). Increasing concentrations of
gremlin were injected in HBS-EP buffer (BIAcore) for 4 minutes (sample volume: 40 L;
flow rate: 5 L/min; dissociation time: 4 minutes). The response (in response units) was
recorded as a function of time. An overlay plot is shown of all sensorgrams after subtraction
of their respective control sensorgrams. Binding parameters, calculated by the nonlinear-
curve–fitting software package BIAevaluation 3.2 (BIAcore Inc) applied to all sensorgrams
simultaneously using a single-site model with drifting baseline, indicate that gremlin/
VEGFR2 interaction occurs with Kd  47  15nM. Under the same experimental condi-
tions, VEGF-A/VEGFR2 interaction occurs with Kd  3  1nM. (B) Gremlin (25nM) was
injected over the sVEGFR2-coated sensor chip in the absence or in the presence of soluble
sVEGFR1-Fc, sVEGFR2-Fc, sVEGFR3-Fc, or sFGFR1-Fc (all at 314nM). Binding data
were plotted as percentage of maximal bound analyte (recorded at the end of injection) and
represent the mean of 2-3 independent experiments. (C) Ninety-six–well plates coated with
100 L of 250 ng/mL sVEGFR1-Fc or sVEGFR2-Fc were incubated with VEGF-A (20 ng/
mL dissolved in phosphate-buffered saline containing 0.1% BSA, 5.0mM (ethylenedini-
trilo)tetraacetic acid, 0.004% Tween 20 in presence of different competitors and incubated
for 1 hour at 37°C followed by 1-hour incubation at room temperature. Bound VEGF-A was
detected with an anti–human VEGF monoclonal antibody (R&D Systems). Gremlin
competes with VEGF-A for the binding to immobilized sVEGFR2-Fc () in a competitive
ELISA for which VEGF-E (E) and FGF2 (‚) were used as positive and negative controls,
respectively. At variance, gremlin did not compete with VEGF-A for the binding to
immobilized sVEGFR1-Fc (f), whereas placenta growth factor (PGIF) () was fully
effective. (D) HUVECs were incubated with 5.0nM gremlin conjugated with the bifunctional
photoactivable biotin-label transfer cross-linker Sulfo-SBED Biotin Label transfer reagent
(Pierce) (sulfo-gremlin) in the absence or in the presence of a molar excess of unlabeled
gremlin or VEGF-A. After ultraviolet irradiation, cell lysates (1.0 mg of protein) were
immunoprecipitated with anti-VEGFR2 antibody (Santa Cruz Biotechnology), separated on
a sodium dodecyl sulfate–polyacrylamide gel electrophoresis gel under reducing conditions
and probed with streptavidin–horseradish peroxidase to visualize the biotin–VEGFR2
complex. Uniform loading of the gel was confirmed by probing the membrane with the
anti-VEGFR2 antibody.
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In keeping with these in vitro observations, the angiogenic
activity exerted by gremlin and VEGF-A ex vivo in the human
umbilical artery ring EC sprouting assay and in vivo in the chick
embryo CAM assay2,3 is significantly inhibited by SU5416, the
VEGFR2 inhibitor I (VEGFR2-KI),12 or by competition with an
excess of free sVEGFR2 (Figure 2F-G; supplemental Figures 6-7).
In all the assays, VEGFR2 inhibitors do not affect the activity of
FGF2 (data not shown).
Here, we demonstrate that the angiogenic activity of gremlin is
mediated by VEGFR2. Most importantly, BMP2 does not prevent
gremlin from binding and activating VEGFR2 (supplemental
Figure 8). Similarly, BMP4 does not affect the angiogenic activity
of gremlin and its interaction with ECs.2 We therefore propose that
distinct domains of gremlin may mediate the interaction with
VEGFR2 or BMPs, respectively.
The capacity of gremlin to bind BMPs and to inhibit their
interaction with the cognate transforming growth factor- family
receptors is thought to play a role in embryonic development13 and
in human diseases.14 However, BMP-independent mechanism(s)
may also be involved in gremlin signaling.2,15 Our data reveal the
previously unrecognized capacity of gremlin to specifically bind to
and promote activation of the major proangiogenic receptor
VEGFR2 in a BMP-independent manner. Thus, gremlin may exert
both BMP-dependent and BMP-independent functions in different
physio-pathologic conditions by inhibiting BMP-mediated trans-
forming growth factor- receptor activation or by a direct activa-
tion of VEGF receptor signaling, respectively. These findings
extend the number of proangiogenic VEGFR2 ligands to a member
of the cystine-knot BMP antagonists distinct from VEGFs.16
Gremlin is expressed by parenchymal and stromal cells in human
tumors.2,4,5 Our observations may provide novel insights for the
understanding of the biology of vascular development and of
angiogenesis-dependent diseases, including cancer.
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autophosphorylation in ECs was not affected by coincubation with a neutralizing anti–VEGF-A antibody (data not shown). (D) Serum-starved HUVECs were stimulated for 0 or
5 minutes with 50 ng/mL gremlin or 30 ng/mL VEGF-A and immunostained with rabbit monoclonal anti–phospho-VEGFR2 antibody (pY1175) followed by Alexa Fluor 488
anti–rabbit IgG (Invitrogen). Samples were analyzed using a Zeiss LSM510Meta confocal microscope equipped with Plan-Apochromat 63/1.4 numerical aperture oil
objective and LSM 510 Meta Software Version 3.5 (Carl Zeiss). Note the presence of the phosphorylated receptor both on HUVEC membrane and in submembrane vesicles in
stimulated cells. (E) HUVEC spheroids prepared in medium supplemented with carboxymethylcellulose were embedded in type I collagen gel and treated with vehicle or
30 ng/mL gremlin or VEGF-A in the absence or in the presence of 3.0M cyclo-VEGI. Formation of radially growing cell sprouts was observed during the next 48 hours.3
Sprouts were photographed at 40 magnification with an IX51 inverted microscope equipped with a 4/0.10 numerical aperture objective and a Camedia C-4040 digital
camera (Olympus). Data are expressed as total number of sprouts measured in 50 spheroids. *Statistically different from the stimulus in the absence of any inhibitor (P  .01,
Student t test). (F) One-millimeter human umbilical artery rings were embedded in fibrin gel and incubated with 50 ng/mL gremlin, 30 ng/mL VEGF-A, or vehicle alone in
absence or in the presence of 5.0M SU5416 or 20nM VEGFR2 kinase inhibitor I (VEGFR2I). After 3 days, EC sprouts, morphologically distinguishable from scattering
fibroblasts/smooth muscle cells, were counted at 100 magnification with an IX51 inverted microscope equipped with a Plan A chromatic phase contrast 10/0.25PhP
numerical aperture objective (Olympus). *Statistically different from gremlin or VEGF-A–treated rings (P  .01, Student t test). (G) Alginate beads containing vehicle, 100 ng of
gremlin, or VEGF-A were implanted on the top of chick embryo CAMs at day 11 of development. When indicated, pellets also contained 150 ng of sVEGFR2 or 5.0M SU5416.
After 72 hours, newly formed blood vessels converging toward the implant were counted in ovo at 5 magnification using a STEMI SR stereomicroscope equipped with an
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